Hydroxysafflor yellow A attenuates left ventricular remodeling after pressure overload-induced cardiac hypertrophy in rats

被引:29
|
作者
Wang, Jianping [1 ]
Zhang, Qing [1 ]
Mei, Xiuhua [1 ]
Zhang, Xiuzhen [1 ]
机构
[1] Yantai Yuhuangding Hosp, Yantai 264000, Shandong, Peoples R China
关键词
Anti-apoptosis; metalloproteinases; Hydroxysafflor Yellow A; left cardiac remodeling; left ventricular remodeling; MATRIX-METALLOPROTEINASE INHIBITION; ESSENTIAL-HYPERTENSION; DYSFUNCTION; APOPTOSIS; MORBIDITY; BCL-2; MASS;
D O I
10.3109/13880209.2013.805791
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Context: Hydroxysafflor yellow A (HSYA), the main chemical component of the safflower yellow pigments, is used extensively in traditional Chinese medicine for the treatment of cerebrovascular and cardiovascular diseases. Objective: The present study determined the effects of HSYA on left ventricular hypertrophy after pressure overload and investigated the underlying mechanisms. Materials and methods: Cardiac hypertrophy was induced by the ligation of abdominal aorta in male Wistar rats. The rats were then divided into five groups and treated with captopril (100 mg/kg) or HSYA at different doses (0, 10, 20 and 40 mg/kg). Six weeks after treatment, the weight of left ventricle, LVMI (left ventricular mass index) and pathological changes were measured. MMP-2 (metalloproteinase 2) and MMP-9 (metalloproteinase 9) levels were determined by ELISA. Protein expressions of Bcl-2 and Bax were evaluated by immunohistochemistry. Results: HSYA (20, 40 mg/kg) significantly attenuated the increase of LVMI (ventricular weight/body weight) by 13.04 and 30.43% respectively, when compared with the model group. This was associated with the amelioration of pathological lesion, such as cardiac muscle fibers were smaller and the nuclei of cardiomyocytes were lightly stained in animals treated with HSYA (20, 40 mg/kg). In addition, the administration of HSYA at doses of 20 and 40 mg/kg increased the Bcl-2/Bax ratio (1.17 +/- 0.08 and 1.39 +/- 0.07 versus 0.71 +/- 0.06). In addition, the serum MMP-2 and MMP-9 levels were blocked by the treatment at doses of 20 and 40 mg/kg HSYA (MMP-2, 76.1 +/- 9.2 and 65.6 +/- 6.8 versus 82.9 +/- 6.2, ng/ml; MMP-9, 66.6 +/- 4.8 and 57.5 +/- 5.0 versus 83.5 +/- 6.0, ng/ml). Conclusion: These findings indicated that HSYA has beneficial effects on hypertensive ventricular remodeling, which may involve mechanisms of inhibiting cell apoptosis and suppressing metalloproteinases expression.
引用
收藏
页码:31 / 35
页数:5
相关论文
共 50 条
  • [21] Renal denervation attenuates pressure overload-induced cardiac remodelling in rats with biphasic regulation of autophagy
    Huo, Jun-Yu
    Jiang, Wan-Ying
    Geng, Jie
    Chen, Chu
    Zhu, Lin
    Chen, Ran
    Ge, Tian-Tian
    Chang, Qing
    Jiang, Zhi-Xin
    Shan, Qi-Jun
    ACTA PHYSIOLOGICA, 2019, 226 (04)
  • [22] Paeoniflorin improves pressure overload-induced cardiac remodeling by modulating the MAPK signaling pathway in spontaneously hypertensive rats
    Liu, Xin
    Chen, Kai
    Zhuang, Yuxin
    Huang, Yu
    Sui, Yukun
    Zhang, Yubin
    Lv, Lin
    Zhang, Guohua
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 111 : 695 - 704
  • [23] Dickkopf-3 attenuates pressure overload-induced cardiac remodelling
    Zhang, Yan
    Liu, Yu
    Zhu, Xue-Hai
    Zhang, Xiao-Dong
    Jiang, Ding-Sheng
    Bian, Zhou-Yan
    Zhang, Xiao-Fei
    Chen, Ke
    Wei, Xiang
    Gao, Lu
    Zhu, Li-Hua
    Yang, Qinglin
    Fan, Guo-Chang
    Lau, Wayne B.
    Ma, Xinliang
    Li, Hongliang
    CARDIOVASCULAR RESEARCH, 2014, 102 (01) : 35 - 45
  • [24] Long-term administration of pyridostigmine attenuates pressure overload-induced cardiac hypertrophy by inhibiting calcineurin signalling
    Lu, Yi
    Zhao, Ming
    Liu, Jin-Jun
    He, Xi
    Yu, Xiao-Jiang
    Liu, Long-Zhu
    Sun, Lei
    Chen, Li-Na
    Zang, Wei-Jin
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2017, 21 (09) : 2106 - 2116
  • [25] Intercellular Adhesion Molecule 1 Regulates Left Ventricular Leukocyte Infiltration, Cardiac Remodeling, and Function in Pressure Overload-Induced Heart Failure
    Salvador, Ane M.
    Nevers, Tania
    Velazquez, Francisco
    Aronovitz, Mark
    Wang, Bonnie
    Molina, Ana Abadia
    Jaffe, Iris Z.
    Karas, Richard H.
    Blanton, Robert M.
    Alcaide, Pilar
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (03):
  • [26] Hydroxysafflor yellow A (HSYA) attenuates hypoxic pulmonary arterial remodelling and reverses right ventricular hypertrophy in rats
    Li, Lei
    Dong, Pengda
    Hou, Congjia
    Cao, Fangyuan
    Sun, Shouli
    He, Fa
    Song, Yanping
    Li, Sen
    Bai, Yuhua
    Zhu, Daling
    JOURNAL OF ETHNOPHARMACOLOGY, 2016, 186 : 224 - 233
  • [27] Zonisamide attenuates pressure overload-induced myocardial hypertrophy in mice through proteasome inhibition
    Wu, Qian
    Liu, Wan-jie
    Ma, Xin-yu
    Chang, Ji-shuo
    Zhao, Xiao-ya
    Liu, Ying-hua
    Yu, Xi-yong
    ACTA PHARMACOLOGICA SINICA, 2024, 45 (04) : 738 - 750
  • [28] Loss of Akap1 Exacerbates Pressure Overload-Induced Cardiac Hypertrophy and Heart Failure
    Schiattarella, Gabriele G.
    Boccella, Nicola
    Paolillo, Roberta
    Cattaneo, Fabio
    Trimarco, Valentina
    Franzone, Anna
    D'Apice, Stefania
    Giugliano, Giuseppe
    Rinaldi, Laura
    Borzacchiello, Domenica
    Gentile, Alessandra
    Lombardi, Assunta
    Feliciello, Antonio
    Esposito, Giovanni
    Perrino, Cinzia
    FRONTIERS IN PHYSIOLOGY, 2018, 9
  • [29] Azilsartan ameliorates ventricular hypertrophy in rats suffering from pressure overload-induced cardiac hypertrophy by activating the Keap1-Nrf2 signalling pathway
    Hou, Ning
    Li, Li-Rong
    Shi, Yong-Ying
    Yuan, Wen-Chang
    Zhao, Gan-Jian
    Liu, Xia-Wen
    Cai, Shao-Ai
    Huang, Yin
    Zhan, Hao-Xin
    Pan, Wei-Biao
    Luo, Cheng-Feng
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2021, 73 (12) : 1715 - 1725
  • [30] Maslinic acid protects against pressure overload-induced cardiac hypertrophy in mice
    Liu, Yan-Ling
    Kong, Chun-Yan
    Song, Peng
    Zhou, Heng
    Zhao, Xing-Sheng
    Tang, Qi-Zhu
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2018, 138 (02) : 116 - 122